Letter | Published:

C-Terminal Half of Immunoglobulin λ Chains

Naturevolume 214pages270272 (1967) | Download Citation

Subjects

Abstract

Two types of chains (ϰ and λ chains) comprise most, if not all, of the heterogeneous population of light chains of pooled normal human gamma-globulins1–3. The C-terminal half of ϰ chains appears to be identical in proteins derived from different clones (myelomas)4–6 except for a single residue which is correlated with a genetic marker6–7. Invariance of the C-terminal half of mouse ϰ chains has also been reported8. A similar situation is found in λ chains. Following a previous report containing the sequence of some sections of the C-terminal half9–10, we propose in this communication the sequence of the C-terminal half of a λ Bence Jones protein (X) (Fig. 1). A second λ Bence Jones protein (Mz) has been compared with the first by isolating tryptic peptides and determining their amino-acid compositions. In a comparison of the two λ chains the only difference detected in the C-terminal half was the substitution of a serine for an arginine molecule at residue 107 (we have kept a unified numbering system for the sequences shown in Fig. 1 in order to simplify the comparison). The position of this substitution (residue 107) is identical to the last position of the N-terminal half of ϰ chains containing sequence variations4. It seems, therefore, that the variable stretches of the sequences of both types of light chains may end in an identical position when the homologous sequences are compared. This is compatible with the hypothesis that the variability of immunoglobulin chains is introduced by a hypermutation process having a well defined starting signal common to all the chains10, although other explanations are not excluded.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Mannik, M., and Kunkel, H. G., J. Exp. Med., 117, 213 (1963).

  2. 2

    Fahey, J. L., J. Immunol., 91, 438 (1963).

  3. 3

    Milstein, C., Nature, 205, 1171 (1965).

  4. 4

    Hilschmann, N., and Craig, L. C., Proc. U.S. Nat. Acad. Sci., 53, 1403 (1965).

  5. 5

    Titani, K., Whitley, E., Avogardo, L., and Putnam, F. W., Science, 149, 1090 (1965).

  6. 6

    Milstein, C., Nature, 209, 370 (1966).

  7. 7

    Baglioni, C., Alescio-Zonta, L., Cioli, D., and Carbonara, A., Science, 152, 1519 (1966).

  8. 8

    Gray, W. R., Dreyer, W. J., and Hood, L., Science, 155, 465 (1967).

  9. 9

    Milstein, C., J. Mol. Biol., 21, 203 (1966).

  10. 10

    Milstein, C., Proc. Roy. Soc., B, 166, 138 (1966).

  11. 11

    Epstein, C., and Motulsky, A. G., in Progress in Medical Genetics (edit. by Steinberg, A. G., and Bearn, H. G.), 4, 85 (1966).

  12. 12

    Milstein, C., Biochem. J., 101, 338 (1966).

  13. 13

    Titani, K., Wikler, M., and Putnam, F. W., Science (in the press).

  14. 14

    Milstein, C., Biochem. J., 101, 352 (1966).

Download references

Author information

Author notes

    • J. B. CLEGG

    Present address: Department of Medicine, University of Liverpool,

Affiliations

  1. Medical Research Council Laboratory of Molecular Biology, Cambridge

    • C. MILSTEIN
    • , J. B. CLEGG
    •  & J. M. JARVIS

Authors

  1. Search for C. MILSTEIN in:

  2. Search for J. B. CLEGG in:

  3. Search for J. M. JARVIS in:

About this article

Publication history

Received

Issue Date

DOI

https://doi.org/10.1038/214270a0

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.